Mangoceuticals, a telehealth company, has made headlines by joining forces with pharmaceutical giants Eli Lilly and Novo Nordisk to offer their weight-loss drugs to self-paying patients. This partnership comes as a result of a recent White House initiative to cut prices of these medications, which could reduce costs by an average of $149 to $350 per month. But here's where it gets controversial... While the U.S. Food and Drug Administration has removed the branded drugs from the shortage list, Mangoceuticals had previously faced legal troubles for selling similar products. The company had filed a lawsuit against online vendors and medical spas for selling copycat weight-loss drugs, claiming they contained the main ingredient, tirzepatide. This partnership allows Mangoceuticals to continue selling Zepbound and Wegovy, but it also raises questions about the ethical boundaries of compounding pharmacies and the potential for price gouging. And this is the part most people miss... The new deal will make these medications more accessible, but it also opens up opportunities for telehealth companies to profit from the weight-loss market. As such, it's important to consider the implications of this partnership and the potential impact on healthcare costs and accessibility. What do you think? Do you agree or disagree with this controversial partnership? Share your thoughts in the comments below!
